Aankondiging • Jun 12
Poxel S.A. Announces CEO Changes Poxel S.A. announced the appointment of Yves Decadt as Chief Executive Officer with effect from June 10, 2026. He succeeded Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. The transition, previously agreed to take place during the first half of 2026, proceeded according to schedule. Yves Decadt has been a member of the Board of Directors since October 21, 2025 and has been heavily involved in defining the Company's strategic and commercial priorities. With over 25 years of international experience in the pharmaceutical industry, Yves Decadt spent nearly 20 years at Johnson & Johnson in the international business development department, responsible for licensing and contract negotiations, with particular expertise in the Asia region. He has also held several senior management positions at leading biopharma and medtech companies. Since August 2025, he has been working with the Poxel teams on a consultancy basis, notably leading an in-depth strategic review of the Company's asset portfolio, which formed the basis for the proposed recovery plan presented to creditors and the Court. It was also under his leadership that the Company finalised the sale of PXL770 to Scynexis, a strategic transaction enabling the monetisation of this asset whilst freeing up the resources necessary for the continued development of Poxel's priority assets. Yves Decadt holds degrees in bioengineering and industrial management from the University of Ghent (Vlerick School), as well as in pharmacology and pharmaceutical medicine from the Université Libre de Bruxelles. He also holds the Board Director certification from Duke University. Aankondiging • Apr 30
Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026 Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026 Board Change • Dec 19
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Sophie Lapointe was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Dec 12
First half 2025 earnings released First half 2025 results: Revenue: €2.18m (up 88% from 1H 2024). Net loss: €2.62m (loss narrowed 64% from 1H 2024). Aankondiging • Nov 27
Poxel S.A., Annual General Meeting, Dec 11, 2025 Poxel S.A., Annual General Meeting, Dec 11, 2025. Location: 12 cours de verdun rambaud esplanade de la gare, lyon France Reported Earnings • Oct 18
Full year 2024 earnings released Full year 2024 results: Revenue: €6.64m (up 235% from FY 2023). Net loss: €18.3m (loss narrowed 48% from FY 2023). New Risk • Jul 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€51m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€33.0m market cap, or US$38.5m). Aankondiging • May 28
Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes Society POXEL SA announced that new clinical and scientific data on TWYMEEG will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations, including results from 7 clinical trials, 3 post-hoc analyses and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) study (Phase 4 study): confirmation of TWYMEEG®? efficacy and safety in diabetic patients with renal impairment; FAMILIAR Study: confirmation of TWYMEE G®? efficacy and safety in combination with DPP-4 inhibitors; PARADIME Clamp: confirmation of TWYMeeG®? dual mechanism of action in diabetic patients - clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part); PARADIME TIR: confirmation of TWYMCEG®? effects on glucose variability; PET/MRI Study: confirmation of TWY MEEG®? effect on glucose excretion in the gut. Aankondiging • Apr 08
Poxel SA Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG®? Package Insert to Include Type 2 Diabetes Patients with Renal Impairment POXEL SA announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG®? package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2. This approval follows positive topline results from the post-marketing clinical study TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) in Japanese type 2 diabetic patients with renal impairment, which confirmed TWYMEEG®®?'s safety and tolerability profile, as announced last August1. Based on these results, discussions with the Japanese regulatory authorities were initiated by Sumitomo Pharma, resulting in the approval that will be officially implemented by Sumitomo Pharma as of April 8, 2025. New Risk • Mar 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.70m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€8.9m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-€51m). Earnings have declined by 6.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (€9.24m market cap, or US$9.70m). Minor Risk Revenue is less than US$5m (€2.2m revenue, or US$2.3m). Reported Earnings • Dec 11
First half 2024 earnings released First half 2024 results: Revenue: €1.16m (up 22% from 1H 2023). Net loss: €7.26m (loss narrowed 72% from 1H 2023). New Risk • Dec 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €7.81m (US$8.26m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€49m). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (€7.81m market cap, or US$8.26m). Minor Risk Revenue is less than US$5m (€2.0m revenue, or US$2.1m). Aankondiging • Nov 08
Poxel S.A. Provides Revenue Guidance for the Full Year 2024 Poxel S.A. provided revenue guidance for the full year 2024. The company to see the good sales trajectory for TWYMEEG in Japan, which should lead to the achievement of JPY 5 billion net sales in the coming months, at which point, Poxel will be entitled to 10% royalties on all TWYMEEG net sales and a sales-based payment of JPY 500 million (EUR 3.1 million).These amounts, based on recent royalty monetization agreement, will serve to start repayment of bonds to OrbiMed. Additionally, Poxel will benefit from the residual amount of the reserve deposit made under the terms of the agreement with OrbiMed, in addition to the USD 42.5 million proceeds received upon closing. Aankondiging • Oct 24
Poxel S.A., Annual General Meeting, Nov 28, 2024 Poxel S.A., Annual General Meeting, Nov 28, 2024. Location: hotel mercure lyon, centre chateau perrache, 12 cours de verdun rambaud esplanade de la gare, lyon France Reported Earnings • Oct 04
Full year 2023 earnings released Full year 2023 results: Revenue: €1.98m (up 194% from FY 2022). Net loss: €35.1m (loss widened 12% from FY 2022). New Risk • Sep 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€42m). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risks Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€29.1m market cap, or US$32.4m). New Risk • Sep 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€42m). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€29.2m market cap, or US$32.4m). New Risk • Aug 19
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€42m). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€35.1m market cap, or US$38.7m). Aankondiging • Aug 07
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan Sumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. New Risk • Jun 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€42m). Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€28.8m market cap, or US$30.9m). New Risk • Apr 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€42m). Earnings have declined by 27% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (34% increase in shares outstanding). Revenue is less than US$5m (€1.5m revenue, or US$1.6m). Market cap is less than US$100m (€25.0m market cap, or US$26.5m). New Risk • Apr 08
New major risk - Revenue and earnings growth Earnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€42m). Earnings have declined by 27% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (34% increase in shares outstanding). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€25.8m market cap, or US$27.9m). Breakeven Date Change • Oct 18
Forecast to breakeven in 2024 The 2 analysts covering Poxel expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% to 2023. The company is expected to make a profit of €26.2m in 2024. Average annual earnings growth of 22% is required to achieve expected profit on schedule. Reported Earnings • Sep 28
First half 2023 earnings released First half 2023 results: Net loss: €26.2m (loss widened 96% from 1H 2022). Revenue is forecast to grow 90% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Aankondiging • May 16
Poxel S.A., Annual General Meeting, Jun 21, 2023 Poxel S.A., Annual General Meeting, Jun 21, 2023, at 09:00 Central European Standard Time. Location: Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France. Lyon France Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Sep 23
First half 2022 earnings released First half 2022 results: Net loss: €13.4m (loss widened 67% from 1H 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Breakeven Date Change • Aug 11
Forecast to breakeven in 2024 The 3 analysts covering Poxel expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €19.5m in 2024. Reported Earnings • May 24
Full year 2021 earnings released: €0.83 loss per share (vs €1.16 loss in FY 2020) Full year 2021 results: €0.83 loss per share (up from €1.16 loss in FY 2020). Revenue: €13.4m (up 97% from FY 2020). Net loss: €23.8m (loss narrowed 25% from FY 2020). Products in clinical trials Phase I: 3 Phase II: 2 Post-clinical trial products Approved (during full year): 1 Launched (during full year): 1 Over the next year, revenue is expected to shrink by 23% compared to a 11% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Mar 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Sep 25
First half 2021 earnings released The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €13.3m (up 108% from 1H 2020). Net loss: €8.03m (loss narrowed 33% from 1H 2020). Reported Earnings • Mar 27
Full year 2020 earnings released The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €6.81m (down 74% from FY 2019). Net loss: €31.9m (loss widened 24% from FY 2019). Is New 90 Day High Low • Jan 18
New 90-day high: €7.60 The company is up 21% from its price of €6.30 on 20 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. Is New 90 Day High Low • Nov 14
New 90-day high: €7.15 The company is up 6.0% from its price of €6.75 on 14 August 2020. The British market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Oct 28
New 90-day low: €5.90 The company is down 9.0% from its price of €6.49 on 29 July 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 